Genital Herpes
7
Pipeline Programs
7
Companies
4
Clinical Trials
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
1
1
0
0
2
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
RNA Therapeutic
150%
Small Molecule
150%
+ 4 programs with unclassified modality
On Market (1)
Approved therapies currently available
Competitive Landscape
6 companies ranked by most advanced pipeline stage
M&
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
NovartisFamciclovir
AiCurisAIC316
ModernamRNA-1608
Merck & Co.HSV 2 Formulation 1
Clinical Trials (4)
Total enrollment: 389 patients across 4 trials
A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding
Start: Jul 2004Est. completion: Oct 2005
Phase 4Completed
Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
Start: Oct 2012Est. completion: Jul 2013
Phase 2Terminated
A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
Start: Sep 2023Est. completion: Apr 2025365 patients
Phase 1/2Completed
Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2
Start: Feb 2020Est. completion: May 202124 patients
Phase 1Terminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
7 companies competing in this space